Alopecia areata in children

Childhood alopecia areata can severely affect quality of life and data are lacking regarding the use of methotrexate in this group of patients

These researchers therefore investigated the safety and efficacy of methotrexate in children with severe alopecia areata. This retrospective study included 14 children aged eight to 18 years who had alopecia areata for a mean duration of 5.7 years. The children received treatment once a week at a mean dose of 18.9mg for a mean duration of 14.2 months. Methotrexate treatment was considered successful in five of the 13 children who were assessed; the remainder were regarded as treatment failures. Methotrexate could cautiously be considered for severe alopecia areata, although further studies are needed to prove its efficacy.
Royer M, Bodemer C, Vabres P et al. Br J Dermatol 2011; 165: 407-10

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Two new steroid inhalers launched

Two new steroid inhalers launched

A new beclometasone metered-dose inhaler and a new...

Half of patients on statins do not reach cholesterol goals, study shows

Half of patients on statins do not reach cholesterol goals, study shows

Half of patients prescribed statins fail to reach their...

First oral hypoglycaemic licensed for add-on therapy in type I diabetes

First oral hypoglycaemic licensed for add-on therapy in type I diabetes

The SGLT2 inhibitor dapagliflozin (Forxiga) can now...

Quick-reference MIMS COPD prescribing resources updated

Quick-reference MIMS COPD prescribing resources updated

Concise MIMS resources on COPD management and antibiotic...